If you need more lookups,
subscriptions start at $34 USD/month.
Odile Rundquist Location
Zürich, ZH, CH
Odile Rundquist Work
Business Development Advisor @ (December 2025 - Present)
Partner @ (October 2023 - Present)
Evaluation Board Member @ (December 2022 - Present)
Scientific Advisor @ (December 2020 - Present)
Board Member @ (November 2021 - December 2023)
Board Member @ (December 2017 - December 2023)
Senior Scientific Advisor @ Family Office - Massellaz AG (March 2016 - June 2023)
Advisory Board Member @ (January 2018 - May 2023)
Senior Pharmaceutical Analyst, Director @ (September 2008 - February 2016)
Pharmaceutical Sell-Side Analyst @ (October 2006 - August 2008)
Pharmaceutical analyst @ (February 2004 - October 2006)
Odile Rundquist Education
Swiss Board School 2018-2019
PhD in Biochemistry, Medical Centre University, Geneva, Switzerland
PhD (biochemistry)
1998-2003
Scripps Research
Diploma Work (Oncology)
1997-1998
Université de Fribourg - Universität Freiburg
Diploma (biochemistry)
1994-1998
Odile Rundquist Skills
Investment Banking
Pharmaceutical Industry
Biotechnology
Financial Analysis
Pharmaceutics
Corporate Finance
Capital Markets
Emerging Markets
Hedge Funds
Equity Research
Equities
Business Strategy
Equity Valuation
Valuation
Venture Capital
Private Equity
Bloomberg
Asset Management
Financial Modeling
Portfolio Management
Derivatives
Data Analysis
Road
PowerPoint
Leadership
Microsoft Office
Microsoft Excel
Biochemistry
Analysis
Public Speaking
Odile Rundquist Summary
Odile Rundquist, based in Zürich, ZH, CH, is currently a Partner at Bioqube Ventures. Odile Rundquist brings experience from previous roles at Superlab Suisse, Wyss Zurich, Bootstrap Europe and Vandria SA. Odile Rundquist holds a 2018 - 2019 Swiss Board School. With a robust skill set that includes Investment Banking, Pharmaceutical Industry, Biotechnology, Financial Analysis, Pharmaceutics and more. Odile Rundquist has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Odile Rundquist?
Find contact details for 700 million professionals.